Clinical Trial Update: A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary Immunodeficiency [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the pharmacokinetics, safety, and tolerability of subcutaneous Gamunex in patients with primary immunodeficiency; results were posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency

Drugs mentioned

• Gamunex (immunoglobulin G (IgG) subcutaneous formulation)

Snippet

Sponsor: Grifols Therapeutics LLC | Conditions: Immunologic Deficiency Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2012-12-18